Gunnar Cario
Overview
Explore the profile of Gunnar Cario including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
3294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Place A, Karol S, Forlenza C, Cooper T, Fraser C, Cario G, et al.
Pediatr Blood Cancer
. 2025 Mar;
:e31630.
PMID: 40062648
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis....
2.
Zeckanovic A, Mouttet B, Vinti L, Ancliff P, Brethon B, Cario G, et al.
Haematologica
. 2025 Feb;
PMID: 39911115
Not available.
3.
Breidenbach M, Bader P, Attarbaschi A, Rossig C, Meisel R, Metzler M, et al.
J Hematol Oncol
. 2025 Jan;
18(1):8.
PMID: 39825416
Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control...
4.
Kempter T, Richter-Pechanska P, Michel K, Rausch T, Erarslan Uysal B, Erarslan-Uysal B, et al.
Blood Adv
. 2025 Jan;
9(6):1267-1279.
PMID: 39808796
Variations in the TP53 and KRAS genes indicate a particularly adverse prognosis in relapsed pediatric T-cell acute lymphoblastic leukemia (T-ALL). We hypothesized that these variations might be subclonally present at...
5.
Kramp L, Heydrich-Karsten C, Sembill S, Karow A, Lion T, Chitadze G, et al.
Ann Hematol
. 2024 Sep;
103(11):4811-4815.
PMID: 39304585
Chronic myeloid leukemia presenting de novo in the blast phase (CML-BP) is a rare diagnosis among pediatric malignancies. We report on a 16-year-old male who presented with CML-BP lymphoid at...
6.
Grasemann C, Hoppner J, Hogler W, Tippelt S, Grasemann M, Grabow D, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Aug;
33(11):1414-1422.
PMID: 39141058
Background: Vitamin D deficiency is linked to poor cancer outcomes but the impact of its consequence, elevated parathyroid hormone (PTH), remains understudied. PTH receptor activation influences cancer progression in vitro,...
7.
Conter V, Valsecchi M, De Lorenzo P, Gandemer V, Heyman M, Saha V, et al.
Haematologica
. 2024 Jul;
109(11):3766-3770.
PMID: 39021218
No abstract available.
8.
Gebing P, Loizou S, Hansch S, Schliehe-Diecks J, Spory L, Stachura P, et al.
Blood Adv
. 2024 Jul;
8(19):4997-5011.
PMID: 39008716
Central nervous system (CNS) involvement remains a clinical hurdle in treating childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The disease mechanisms of CNS leukemia are primarily investigated using 2-dimensional cell...
9.
Hovorkova L, Winkowska L, Skorepova J, Krumbholz M, Benesova A, Polivkova V, et al.
Mol Cancer
. 2024 Jul;
23(1):138.
PMID: 38970095
Background: The BCR::ABL1 is a hallmark of chronic myeloid leukemia (CML) and is also found in acute lymphoblastic leukemia (ALL). Most genomic breaks on the BCR side occur in two...
10.
Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, et al.
Lancet Oncol
. 2024 Jun;
25(7):922-932.
PMID: 38936379
Background: Neuroblastoma is the most common extracranial solid tumour in children. Relapsed or refractory neuroblastoma is associated with a poor outcome. We assessed the combination of irinotecan-temozolomide and dasatinib-rapamycin (RIST)...